Czech National Bank Raises Stock Holdings in Solventum Corporation $SOLV

Czech National Bank raised its position in shares of Solventum Corporation (NYSE:SOLV) by 6.6% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 33,832 shares of the company’s stock after purchasing an additional 2,089 shares during the period. Czech National Bank’s holdings in Solventum were worth $2,566,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Independent Franchise Partners LLP boosted its holdings in Solventum by 263.1% during the 1st quarter. Independent Franchise Partners LLP now owns 5,820,724 shares of the company’s stock valued at $442,608,000 after acquiring an additional 4,217,570 shares during the period. Boston Partners raised its holdings in Solventum by 101.3% in the first quarter. Boston Partners now owns 3,361,973 shares of the company’s stock worth $255,554,000 after purchasing an additional 1,691,565 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in Solventum by 738.3% during the 1st quarter. Assenagon Asset Management S.A. now owns 566,623 shares of the company’s stock valued at $43,086,000 after acquiring an additional 499,031 shares during the period. Nuveen LLC purchased a new position in shares of Solventum during the first quarter valued at approximately $35,375,000. Finally, Wedge Capital Management L L P NC boosted its holdings in Solventum by 570.0% in the first quarter. Wedge Capital Management L L P NC now owns 504,392 shares of the company’s stock worth $38,354,000 after acquiring an additional 429,109 shares in the last quarter.

Analyst Upgrades and Downgrades

SOLV has been the topic of several analyst reports. KeyCorp assumed coverage on shares of Solventum in a research note on Friday, June 6th. They issued a “sector weight” rating on the stock. Zacks Research raised Solventum from a “hold” rating to a “strong-buy” rating in a report on Monday, September 15th. Wall Street Zen downgraded Solventum from a “strong-buy” rating to a “buy” rating in a report on Tuesday, September 9th. Argus upgraded Solventum from a “hold” rating to a “buy” rating and set a $90.00 price objective for the company in a report on Tuesday, July 1st. Finally, Piper Sandler restated an “overweight” rating and set a $94.00 target price (up previously from $87.00) on shares of Solventum in a research note on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $85.44.

Solventum Trading Down 0.8%

Shares of SOLV stock opened at $73.77 on Friday. The company has a current ratio of 1.22, a quick ratio of 0.86 and a debt-to-equity ratio of 2.14. The stock has a market capitalization of $12.79 billion, a price-to-earnings ratio of 34.15, a price-to-earnings-growth ratio of 3.03 and a beta of 0.53. Solventum Corporation has a 12-month low of $60.70 and a 12-month high of $85.92. The stock’s 50-day moving average price is $72.98 and its 200-day moving average price is $72.41.

Solventum (NYSE:SOLV) last released its quarterly earnings results on Thursday, August 7th. The company reported $1.69 earnings per share for the quarter, beating the consensus estimate of $1.45 by $0.24. Solventum had a return on equity of 29.93% and a net margin of 4.52%.The business had revenue of $2.16 billion during the quarter, compared to analysts’ expectations of $2.12 billion. During the same quarter last year, the business posted $1.56 EPS. The firm’s revenue for the quarter was up 3.8% compared to the same quarter last year. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. Equities research analysts predict that Solventum Corporation will post 6.58 EPS for the current fiscal year.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.